Wednesday, March 27, 2013

Carbapenem-resistant Enterobacteriaceae (CRE)

Applicability: Infection preventionists
Source: CDC Health Advisory

Carbapenem-resistant Enterobacteriaceae (CRE) are untreatable or difficult-to-treat multidrug-resistant organisms that are emerging in the United States. Because of increased reports of these multidrug-resistant organisms, CDC is alerting clinicians about the need for additional prevention steps regarding CRE. Some key points include:

- While still uncommon, reports of unusual forms of CRE (e.g., New Delhi Metallo-β-lactamase and Verona Integron-mediated Metallo-β-lactamase) in the United States are increasing. Of the 37 unusual forms of CRE that have been reported in the United States, the last 15 have been reported since July, 2012.

- This increase highlights the need for U.S. healthcare providers to act aggressively to prevent the emergence and spread of these unusual CRE organisms.

- The vast majority of these unusual organisms were isolated from patients who received overnight medical treatment outside of the United States.

For more information, refer to CDC guidance ( ) which addresses key elements of CRE prevention (e.g., use of Contact Precautions) in healthcare settings.